Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2023 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks: does management convey that deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago? We need to look for a comparison against the company's own recent past, already real and recurring, and early stage. In the transcript, management discusses Vyleesi growth, but that's about revenue and prescriptions, not necessarily about deal size. They mention "six consecutive quarters of double-digit growth" but that's about sales volume, not about individual deals being larger. They discuss licensing deals: Fosun Pharma in China, Kwangdong in South Korea. But they don't compare sizes of those deals to past deals. They discuss potential partnerships for other programs, but that's future. They discuss the erectile dysfunction program, but that's new. They discuss dry eye disease trial, but that's a clinical trial, not a deal. The question is about "successive engagements of the same kind" coming in at progressively larger size. For example, if they were licensing Vyleesi to different partners and each new license was larger in scope or value, that would count. But they don't say that. They mention "multiple ongoing discussions with potential partners" but that's not about size. They mention "we have multiple shots on the goal for cash flow coming in" but that's not about size. They mention "we are planning to initiate clinical programs" but that's not about deals. They mention "we have developed a co-formulation" but that's a product. They mention "we have already initiated regulatory discussions with the FDA" for glaucoma, but that's not about deal size. The only thing that might be relevant is the Vyleesi licensing deals. But they don't say that the new deals are bigger than the old ones. They just report progress. Also, they mention "we are pleased with Vyleesi's quarter-over-quarter double-digit increases across all value metrics." That's about sales, not about deal size. The question specifically asks about "deals, orders, contracts, projects, customers, sites, or programs" that are individually bigger. The transcript does not contain such a statement.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.